X4 Pharmaceuticals (XFOR) Interest Expenses (2017 - 2025)

X4 Pharmaceuticals has reported Interest Expenses for 9 years, with the latest figure at $2.2 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses fell 5.12% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2025 stood at $8.9 million (up 1.23% YoY), and the FY2025 full-year result was $8.9 million, up 1.23% from the prior year.
• Interest Expenses for Q4 2025 stood at $2.2 million, down from $2.3 million in the prior quarter.
• The five-year high for Interest Expenses was $2.4 million in Q3 2024, with the low at $891000.0 in Q1 2021.
• Historically, Interest Expenses has averaged $1.6 million across 5 years, with a median of $1.4 million in 2023.
• Annual changes were most pronounced in 2024 — Interest Expenses surged 89.55% — and 2025, when it dropped 6.5%.
• X4 Pharmaceuticals' Interest Expenses stood at $925000.0 in 2021, then climbed by 23.68% to $1.1 million in 2022, then surged by 64.86% to $1.9 million in 2023, then grew by 22.16% to $2.3 million in 2024, then dropped by 5.12% to $2.2 million in 2025.
• The last three Interest Expenses figures came in at $2.2 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.